Clinical Evidence
What the Evidence Shows
Each finding below is linked to its primary source. Confidence levels reflect the quality and quantity of available evidence — not CelluTarget's endorsement of any treatment.
Note on negative evidence: Studies on this treatment in MMN have not demonstrated clear, proven efficacy. CelluTarget includes documented negative results because knowing what doesn't work is as important as knowing what does — and helps patients and physicians avoid ineffective treatments.
High: Supported by multiple robust studies or regulatory approval
Moderate: Supported by limited controlled studies or consistent case series
Low: Based on case reports, expert opinion, or early-phase data only
Moderate ConfidenceSupported by limited controlled studies or consistent case series
Peer ReviewedProspects for multifocal motor neuropathy treatment by complement inhibition (review; eculizumab/ravulizumab efficacy not established)
Published January 2025
View source ↗